BridgeBio Oncology Therapeutics Inc (BBOT) Price Prediction & ForecastBBOTBridgeBio Oncology Therapeutics Inc

Alphio's BBOT stock price prediction model matches the current BridgeBio Oncology Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.15 (-1.70%). The 1-week path is $2.13 (-2.31%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Helix Acquisition Corp II (BBOT) is not a good buy right now due to its significantly low price and negative financial indicators. The current price is $2.31, which is 81.20% lower than its year-to-date performance. Additionally, the RSI is at a very low 19.05, indicating oversold conditions, but this is not a strong enough signal to justify a purchase given the ongoing losses. The company reported a net income loss of $56.45 million in Q2 2026 and has a forward P/E ratio of 0, indicating no earnings growth expected in the near future. The main risk is the continued decline in stock value, as evidenced by a 12.50% drop over the last five days and an 81.20% decline over the past year.

BridgeBio Oncology Therapeutics Inc (BBOT) last closed at $2.1849999, losing -5.00%. These facts feed the 1-day and 1-week BBOT price prediction above.